APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

G-CSF Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global G-CSF Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173993620319 December 2025195 pages

Choose your research edition.

Industry ResearchG-CSF Biosimilars Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal G-CSF Biosimilars Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal G-CSF Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal G-CSF Biosimilars Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal G-CSF Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global G-CSF Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of G-CSF Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, GlaxoSmithKline, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global G-CSF Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of G-CSF Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents G-CSF Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the G-CSF Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

G-CSF Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

GlaxoSmithKline

Bayer

Amgen

AbbVie

AstraZeneca

Gilead Science

G-CSF Biosimilars Segment by Type

Insulin

Human Growth Hormone

Granulocyte-Colony Stimulating Factor

Interferon

Monoclonal Antibodies

Erythropoietin

G-CSF Biosimilars Segment by Application

Chronic And Autoimmune Diseases

Growth Hormone Deficiencies

Blood Disorders

Oncology Diseases

G-CSF Biosimilars Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global G-CSF Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of G-CSF Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of G-CSF Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the G-CSF Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of G-CSF Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of G-CSF Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. G-CSF Biosimilars Industry Trends Table 2. G-CSF Biosimilars Industry Drivers Table 3. G-CSF Biosimilars Industry Opportunities and Challenges Table 4. G-CSF Biosimilars Industry Restraints Table 5. Global G-CSF Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global G-CSF Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global G-CSF Biosimilars Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global G-CSF Biosimilars Sales Market Share by Manufacturers Table 9. Global G-CSF Biosimilars Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global G-CSF Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global G-CSF Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global G-CSF Biosimilars Manufacturers, Product Type & Application Table 13. Global G-CSF Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global G-CSF Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Insulin Table 17. Major Manufacturers of Human Growth Hormone Table 18. Major Manufacturers of Granulocyte-Colony Stimulating Factor Table 19. Major Manufacturers of Interferon Table 20. Major Manufacturers of Monoclonal Antibodies Table 21. Major Manufacturers of Erythropoietin Table 22. Global G-CSF Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global G-CSF Biosimilars Sales by Type (2021-2026) & (K Units) Table 24. Global G-CSF Biosimilars Sales by Type (2027-2032) & (K Units) Table 25. Global G-CSF Biosimilars Sales Market Share by Type (2021-2026) Table 26. Global G-CSF Biosimilars Sales Market Share by Type (2027-2032) Table 27. Global G-CSF Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global G-CSF Biosimilars Revenue by Type (2021-2026) & (K Units) Table 29. Global G-CSF Biosimilars Revenue by Type (2027-2032) & (K Units) Table 30. Global G-CSF Biosimilars Revenue Market Share by Type (2021-2026) Table 31. Global G-CSF Biosimilars Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Chronic And Autoimmune Diseases Table 33. Major Manufacturers of Growth Hormone Deficiencies Table 34. Major Manufacturers of Blood Disorders Table 35. Major Manufacturers of Oncology Diseases Table 36. Global G-CSF Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global G-CSF Biosimilars Sales by Application (2021-2026) & (K Units) Table 38. Global G-CSF Biosimilars Sales by Application (2027-2032) & (K Units) Table 39. Global G-CSF Biosimilars Sales Market Share by Application (2021-2026) Table 40. Global G-CSF Biosimilars Sales Market Share by Application (2027-2032) Table 41. Global G-CSF Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global G-CSF Biosimilars Revenue by Application (2021-2026) & (K Units) Table 43. Global G-CSF Biosimilars Revenue by Application (2027-2032) & (K Units) Table 44. Global G-CSF Biosimilars Revenue Market Share by Application (2021-2026) Table 45. Global G-CSF Biosimilars Revenue Market Share by Application (2027-2032) Table 46. Global G-CSF Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global G-CSF Biosimilars Sales by Region (2021-2026) & (K Units) Table 48. Global G-CSF Biosimilars Sales Market Share by Region (2021-2026) Table 49. Global G-CSF Biosimilars Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global G-CSF Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 51. North America G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 53. North America G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 54. Europe G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 56. Europe G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 63. Global G-CSF Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global G-CSF Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 65. Global G-CSF Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 66. Global G-CSF Biosimilars Revenue Market Share by Region (2021-2026) Table 67. Global G-CSF Biosimilars Revenue Market Share by Region (2027-2032) Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sanofi G-CSF Biosimilars Product Portfolio Table 72. Sanofi Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Johnson & Johnson G-CSF Biosimilars Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis G-CSF Biosimilars Product Portfolio Table 82. Novartis Recent Development Table 83. Merck & Co. Company Information Table 84. Merck & Co. Business Overview Table 85. Merck & Co. G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Merck & Co. G-CSF Biosimilars Product Portfolio Table 87. Merck & Co. Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Roche G-CSF Biosimilars Product Portfolio Table 92. Roche Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Pfizer G-CSF Biosimilars Product Portfolio Table 97. Pfizer Recent Development Table 98. GlaxoSmithKline Company Information Table 99. GlaxoSmithKline Business Overview Table 100. GlaxoSmithKline G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. GlaxoSmithKline G-CSF Biosimilars Product Portfolio Table 102. GlaxoSmithKline Recent Development Table 103. Bayer Company Information Table 104. Bayer Business Overview Table 105. Bayer G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bayer G-CSF Biosimilars Product Portfolio Table 107. Bayer Recent Development Table 108. Amgen Company Information Table 109. Amgen Business Overview Table 110. Amgen G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Amgen G-CSF Biosimilars Product Portfolio Table 112. Amgen Recent Development Table 113. AbbVie Company Information Table 114. AbbVie Business Overview Table 115. AbbVie G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. AbbVie G-CSF Biosimilars Product Portfolio Table 117. AbbVie Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. AstraZeneca G-CSF Biosimilars Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Gilead Science Company Information Table 124. Gilead Science Business Overview Table 125. Gilead Science G-CSF Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Gilead Science G-CSF Biosimilars Product Portfolio Table 127. Gilead Science Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. G-CSF Biosimilars Distributors List Table 131. G-CSF Biosimilars Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. G-CSF Biosimilars Product Image Figure 2. Global G-CSF Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global G-CSF Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global G-CSF Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global G-CSF Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 G-CSF Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Insulin Image Figure 9. Human Growth Hormone Image Figure 10. Granulocyte-Colony Stimulating Factor Image Figure 11. Interferon Image Figure 12. Monoclonal Antibodies Image Figure 13. Erythropoietin Image Figure 14. Global G-CSF Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global G-CSF Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global G-CSF Biosimilars Sales Market Share by Type (2021-2032) Figure 17. Global G-CSF Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global G-CSF Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global G-CSF Biosimilars Revenue Market Share by Type (2021-2032) Figure 20. Chronic And Autoimmune Diseases Image Figure 21. Growth Hormone Deficiencies Image Figure 22. Blood Disorders Image Figure 23. Oncology Diseases Image Figure 24. Global G-CSF Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global G-CSF Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global G-CSF Biosimilars Sales Market Share by Application (2021-2032) Figure 27. Global G-CSF Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global G-CSF Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global G-CSF Biosimilars Revenue Market Share by Application (2021-2032) Figure 30. North America G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 32. U.S. G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 37. Germany G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 44. China G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 52. Brazil G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile G-CSF Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global G-CSF Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global G-CSF Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America G-CSF Biosimilars Revenue (2021-2032) & (US$ Million) Figure 63. North America G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe G-CSF Biosimilars Revenue (2021-2032) & (US$ Million) Figure 65. Europe G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific G-CSF Biosimilars Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa G-CSF Biosimilars Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. G-CSF Biosimilars Value Chain Figure 71. Manufacturing Cost Structure Figure 72. G-CSF Biosimilars Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin
  • Human Growth Hormone
  • Granulocyte-Colony Stimulating Factor
  • Interferon
  • Monoclonal Antibodies
  • Erythropoietin
Applications
  • Chronic And Autoimmune Diseases
  • Growth Hormone Deficiencies
  • Blood Disorders
  • Oncology Diseases
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Gilead Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global G-CSF Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global G-CSF Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global G-CSF Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global G-CSF Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global G-CSF Biosimilars Market Dynamics
  1. 2.1 G-CSF Biosimilars Industry Trends
  2. 2.2 G-CSF Biosimilars Industry Drivers
  3. 2.3 G-CSF Biosimilars Industry Opportunities and Challenges
  4. 2.4 G-CSF Biosimilars Industry Restraints
3 G-CSF Biosimilars Market by Manufacturers
  1. 3.1 Global G-CSF Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global G-CSF Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global G-CSF Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global G-CSF Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global G-CSF Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global G-CSF Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global G-CSF Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global G-CSF Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 G-CSF Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 G-CSF Biosimilars Tier 1, Tier 2, and Tier 3
4 G-CSF Biosimilars Market by Type
  1. 4.1 G-CSF Biosimilars Type Introduction
  2. 4.1.1 Insulin
  3. 4.1.2 Human Growth Hormone
  4. 4.1.3 Granulocyte-Colony Stimulating Factor
  5. 4.1.4 Interferon
  6. 4.1.5 Monoclonal Antibodies
  7. 4.1.6 Erythropoietin
  8. 4.2 Global G-CSF Biosimilars Sales by Type
  9. 4.2.1 Global G-CSF Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global G-CSF Biosimilars Sales by Type (2021-2032)
  11. 4.2.3 Global G-CSF Biosimilars Sales Market Share by Type (2021-2032)
  12. 4.3 Global G-CSF Biosimilars Revenue by Type
  13. 4.3.1 Global G-CSF Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global G-CSF Biosimilars Revenue by Type (2021-2032)
  15. 4.3.3 Global G-CSF Biosimilars Revenue Market Share by Type (2021-2032)
5 G-CSF Biosimilars Market by Application
  1. 5.1 G-CSF Biosimilars Application Introduction
  2. 5.1.1 Chronic And Autoimmune Diseases
  3. 5.1.2 Growth Hormone Deficiencies
  4. 5.1.3 Blood Disorders
  5. 5.1.4 Oncology Diseases
  6. 5.2 Global G-CSF Biosimilars Sales by Application
  7. 5.2.1 Global G-CSF Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global G-CSF Biosimilars Sales by Application (2021-2032)
  9. 5.2.3 Global G-CSF Biosimilars Sales Market Share by Application (2021-2032)
  10. 5.3 Global G-CSF Biosimilars Revenue by Application
  11. 5.3.1 Global G-CSF Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global G-CSF Biosimilars Revenue by Application (2021-2032)
  13. 5.3.3 Global G-CSF Biosimilars Revenue Market Share by Application (2021-2032)
6 Global G-CSF Biosimilars Sales by Region
  1. 6.1 Global G-CSF Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global G-CSF Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global G-CSF Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global G-CSF Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America G-CSF Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe G-CSF Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific G-CSF Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa G-CSF Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa G-CSF Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global G-CSF Biosimilars Revenue by Region
  1. 7.1 Global G-CSF Biosimilars Revenue by Region
  2. 7.1.1 Global G-CSF Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global G-CSF Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global G-CSF Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global G-CSF Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America G-CSF Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe G-CSF Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific G-CSF Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa G-CSF Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa G-CSF Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi G-CSF Biosimilars Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson G-CSF Biosimilars Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis G-CSF Biosimilars Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck & Co.
  20. 8.4.1 Merck & Co. Company Information
  21. 8.4.2 Merck & Co. Business Overview
  22. 8.4.3 Merck & Co. G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co. G-CSF Biosimilars Product Portfolio
  24. 8.4.5 Merck & Co. Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche G-CSF Biosimilars Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer G-CSF Biosimilars Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline G-CSF Biosimilars Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer G-CSF Biosimilars Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen G-CSF Biosimilars Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie G-CSF Biosimilars Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca G-CSF Biosimilars Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Gilead Science
  68. 8.12.1 Gilead Science Company Information
  69. 8.12.2 Gilead Science Business Overview
  70. 8.12.3 Gilead Science G-CSF Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Science G-CSF Biosimilars Product Portfolio
  72. 8.12.5 Gilead Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 G-CSF Biosimilars Value Chain Analysis
  2. 9.1.1 G-CSF Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 G-CSF Biosimilars Production Mode & Process
  6. 9.2 G-CSF Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 G-CSF Biosimilars Distributors
  9. 9.2.3 G-CSF Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst